TPG GP A’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-427,718
Closed -$101M 35
2023
Q4
$101M Buy
427,718
+68,081
+19% +$13.4M 1.63% 18
2023
Q3
$70.5M Buy
359,637
+31,168
+9% +$6.4M 1.22% 21
2023
Q2
$69.1M Buy
328,469
+32,402
+11% +$6.45M 1.01% 22
2023
Q1
$59.8M Sell
296,067
-6,196
-2% -$1.4M 0.97% 23
2022
Q4
$65.9M Buy
+302,263
New +$66M 1.29% 22

Other funds holding CRL

TPG GP A's CRL Position: Q1 2024 in Review

TPG GP A sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 427,718 shares — an estimated $101M sold.

TPG GP A first reported a position in CRL in Q4 2022 and held it in 5 quarters. The position peaked at $101M in Q4 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • TPG GP A reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • TPG GP A sold 427,718 Charles River Laboratories shares in Q1 2024, an estimated $101M.
  • TPG GP A first reported a position in Charles River Laboratories in Q4 2022 and held it in 5 quarters.
  • TPG GP A's Charles River Laboratories position peaked at $101M in Q4 2023.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on TPG GP A's 13F filing for Q1 2024, filed 15 May 2024.